Myocardial dysfunction in sepsis;Disfunción miocárdica en la sepsis

Revista Medica de Chile

Volumn 138, Issue 7, 2010, Pages 888-896

  Andresen, Max ^a   Regueira, Tomás ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cardiomyopathies; Heart failure; Sepsis

Indexed keywords

ARTICLE; CARDIOMYOPATHY; HUMAN; PATHOPHYSIOLOGY; SEPSIS;

CARDIOMYOPATHIES; HUMANS; SEPSIS;

EID: 78549253141     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004; 8: 222-6.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
3. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.
4. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274: 968-74.
5. Rabuel C, Mebazaa A. Septic shock: a heart story since the 1960s. Intensive Care Med 2006; 32: 799-807.
6. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100: 483-90.
7. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE. Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest 1988; 93: 903-10.
8. Parker MM, Mccarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990; 97: 126-31.
9. Calvin JE, Driedger AA, Sibbald WJ. An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. Chest 1981; 80: 579-86.
10. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 1997; 23: 553-60.
11. Jardin F, Fourme T, Page B, Loubieres Y, Vieillard-Baron A, Beauchet A, et al. Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. Chest 1999; 116: 1354-9.
12. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008; 36: 1701-6.
13. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32: 660-5.
14. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parrillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987; 15: 923-9.
15. Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds Rm, Bennett ED. A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock. Crit Care Med 1999; 27: 2361-6.
16. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med 1999; 27: 1775-80.
17. Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med 2000; 26: 31-7.
18. Ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000; 46: 650-7.
19. Fernandes CJ Jr, Akamine N, Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med 1999; 25: 1165-8.
20. Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29: 1696-702.
21. Rivers EP, Mccord J, Otero R, Jacobsen G, Loomba M. Clinical utility of B-type natriuretic peptide in early severe sepsis and septic shock. J Intensive Care Med 2007; 22: 363-73.
22. Tung RH, García C, Morss AM, Pino RM, Fifer MA, Thompson BT, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32: 1643-7.
23. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation 1986; 73: 637-44.
24. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27: 1230-51.
25. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76: 1539-53.
26. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004; 363: 203-9.
27. Garner LB, Willis MS, Carlson DL, Dimaio JM, White MD, White DJ, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 2003; 285: H2500-9.
28. SN, Kasian K, Jacobs H, Cheng ZQ, Light RB. N,N'-diacetylchitobiose, an inhibitor of lysozyme, reverses myocardial depression and lessens norepinephrine requirements in Escherichia coli sepsis in dogs. Shock 2008; 29: 681-7.
29. Konrad D, Oldner A, Rossi P, Wanecek M, Rudehill A, Weitzberg E. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock. Crit Care Med 2004; 32: 1192-9.
30. Niederbichler AD, Hoesel LM, Westfall MV, Gao H, Ipaktchi KR, Sun L, et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 2006; 203: 53-61.
31. Ullrich R, Scherrer-Crosbie M, Bloch KD, Ichinose F, Nakajima H, Picard MH, et al. Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocardial dysfunction in mice. Circulation 2000; 102: 1440-6.
32. Brady AJ, Poole-Wilson PA. Circulatory failure in septic shock. Nitric oxide: too much of a good thing? Br Heart J 1993; 70: 103-5.
33. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000; 87: 241-7.
34. Andresen M, Regueira T, Bruhn A, Pérez D, Strobel P, Dougnac A, et al. Lipoperoxidation and protein oxidative damage exhibit different kinetics during septic shock. Mediators Inflamm 2008:168652.doi 10.1155/2008/168652
35. Chen Y, Traverse JH, Du R, Hou M, Bache RJ. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 2002; 106: 273-9.
36. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003; 299: 896-9.
37. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-9.
38. Chagnon F, Bentourkia M, Lecomte R, Lessard M, Lesur O. Endotoxin-induced heart dysfunction in rats: assessment of myocardial perfusion and permeability and the role of fluid resuscitation. Crit Care Med 2006; 34: 127-33.
39. Groeneveld AB, Van Lambalgen AA, Van Den Bos GC, Bronsveld W, Nauta JJ, Thijs LG. Maldistribution of heterogeneous coronary blood flow during canine endotoxin shock. Cardiovasc Res 1991; 25: 80-8.
40. Mink SN, Bose R, Roberts DE, Jacobs H, Duke K, Bose D, et al. Lysozyme binding to endocardial endothelium mediates myocardial depression by the nitric oxide guanosine 3',5' monophosphate pathway in sepsis. J Mol Cell Cardiol 2005; 39: 615-25.
41. Madorin WS, Rui T, Sugimoto N, Handa O, Cepinskas G, Kvietys PR. Cardiac myocytes activated by septic plasma promote neutrophil transendothelial migration: role of platelet-activating factor and the chemokines LIX and KC. Circ Res 2004; 94: 944-51.
42. Lew WY, Yasuda S, Yuan T, Hammond HK. Endotoxin-induced cardiac depression is associated with decreased cardiac dihydropyridine receptors in rabbits. J Mol Cell Cardiol 1996; 28: 1367-71.
43. Zhong J, Hwang TC, Adams HR, Rubin LJ. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol 1997; 273: H2312-24.
44. Tavernier B, Mebazaa A, Mateo P, Sys S, Ventura-Clapier R, Veksler V. Phosphorylation-dependent alteration in myofilament ca2+ sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med 2001; 163: 362-7.
45. Dong LW, Wu LL, Ji Y, Liu MS. Impairment of the ryanodine-sensitive calcium release channels in the cardiac sarcoplasmic reticulum and its underlying mechanism during the hypodynamic phase of sepsis. Shock 2001; 16: 33-9.
46. Wu LL, Tang C, Dong LW, Liu MS. Altered phospholamban-calcium ATPase interaction in cardiac sarcoplasmic reticulum during the progression of sepsis. Shock 2002; 17: 389-93.
47. Kreymann G, Grosser S, Buggisch P, Gottschall C, Matthaei S, Greten H. Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock. Crit Care Med 1993; 21: 1012-9.
48. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35: 1599-1608.
49. Boekstegers P, Weidenhofer S, Kapsner T, Werdan K. Skeletal muscle partial pressure of oxygen in patients with sepsis. Crit Care Med 1994; 22: 640-50.
50. Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, Dall'ava-Santucci J, Brunet F, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75: 533-41.
51. Rossi MA, Celes MR Prado CM, Saggioro FP. Myocardial structural changes in long-term human severe sepsis/ septic shock may be responsible for cardiac dysfunction. Shock 2007; 27: 10-8.
52. Sharshar T, Annane D, De La Grandmaison GL, Brouland JP, Hopkinson NS, Francoise G. The neuropathology of septic shock. Brain Pathol 2004; 14: 21-33.
53. Fernandes Junior CJ, Iervolino M, Neves RA, Sampaio EL, Knobel E. Interstitial myocarditis in sepsis. Am J Cardiol 1994; 74: 958.
54. Fauvel H, Marchetti P, Chopin C, Formstecher P, Neviere R. Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. Am J Physiol Heart Circ Physiol 2001; 280: H1608-14.
55. Lancel S, Joulin O, Favory R, Goossens JF, Kluza J, Chopin C, et al. Ventricular myocyte caspases are directly responsible for endotoxin-induced cardiac dysfunction. Circulation 2005; 111: 2596-604.
56. Fauvel H, Marchetti P, Obert G, Joulain O, Chopin C, Formstecher P, et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. Am J Respir Crit Care Med 2002; 165: 449-55.
57. Regueira T, Andresen M, Djafarzadeh S. [Mitochondrial dysfunction during sepsis, impact and possible regulating role of hypoxia-inducible factor -1?]. Med Intensiva 2009; 33: 385-92.
58. Brealey D, Karyampudi S, Jacques TS, Novelli M, Stidwill R, Taylor V, et al. Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004; 286: R491-7.
59. Crouser ED, Julian MW, Huff JE, Joshi MS, Bauer JA, Gadd ME, et al. Abnormal permeability of inner and outer mitochondrial membranes contributes independently to mitochondrial dysfunction in the liver during acute endotoxemia. Crit Care Med 2004; 32: 478-88.
60. Schumer W, Erve PR, Obernolte RP. Endotoxemic effect on cardiac and skeletal muscle mitochondria. Surg Gynecol Obstet 1971; 133: 433-6.
61. Soriano FG, Nogueira AC, Caldini EG, Lins MH, Teixeira AC, Cappi SB, et al. Potential role of poly (adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med 2006; 34: 1073-9.
62. Trumbeckaite S, Opalka Jr, Neuhof C, Zierz S, Gellerich FN. Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. Eur J Biochem 2001; 268: 1422-9.
63. Gellerich FN, Trumbeckaite S, Hertel K, Zierz S, Muller-Werdan U, Werdan K, et al. Impaired energy metabolism in hearts of septic baboons: diminished activities of Complex I and Complex II of the mitochondrial respiratory chain. Shock 1999; 11: 336-41.
64. Vary TC, Siegel JH, Nakatani T, Sato T, Aoyama H. Effect of sepsis on activity of pyruvate dehydrogenase complex in skeletal muscle and liver. Am J Physiol 1986; 250: E634-40.
65. Vary TC. Increased pyruvate dehydrogenase kinase activity in response to sepsis. Am J Physiol 1991; 260: E669-74.
66. Szabo C. Poly (ADP-ribose) polymerase activation and circulatory shock. Novartis Found Symp 2007; 280: 92-103; discussion 103-107, 160-104.
67. Bolanos JP, Heales SJ, Peuchen S, Barker JE, Land JM, Clark JB. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic Biol Med 1996; 21: 995-1001.
68. Ed, Julian MW, Huff JE, Struck J, Cook CH. Carbamoyl phosphate synthase-1: a marker of mitochondrial damage and depletion in the liver during sepsis. Crit Care Med 2006; 34: 2439-46.
69. Regueira T, Lepper PM, Brandt S, Ochs M, Vuda M, Takala J, et al. Hypoxia inducible factor-1 alpha induction by tumour necrosis factor-alpha, but not by toll-like receptor agonists, modulates cellular respiration in cultured human hepatocytes. Liver Int 2009; 29: 1582-92.
70. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004; 364: 1786-8.
71. Bocking JK, Sibbald WJ, Holliday RL, Scott S, Viidik T. Plasma catecholamine levels and pulmonary dysfunction in sepsis. Surg Gynecol Obstet 1979; 148: 715-9.
72. Macarthur H, Westfall TC, Riley DP, Misko TP, Salvemini D. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci U S A 2000; 97: 9753-8.
73. Tang C, Liu MS. Initial externalization followed by internalization of beta-adrenergic receptors in rat heart during sepsis. Am J Physiol 1996; 270: R254-63.
74. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989; 86: 6753-7.
75. Bohm M, Kirchmayr R, Gierschik P, Erdmann E. Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure. Am J Med 1995; 98: 183-6.
76. Faivre V, Kaskos H, Callebert J, Losser Mr, Milliez P, Bonnin P, et al. Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide-treated rabbits. Anesthesiology 2005; 103: 514-21.
77. Fernandes CJ, JR. One more piece in the septic myocardial depression puzzle? Crit Care Med 2005; 33: 690-691.
78. Cobb JP. Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise. Surg Infect (Larchmt) 2001; 2: 93-100; discussion 100-1.
79. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-702.
80. Supinski GS, Murphy MP, Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1095-102.